One of the most frequently asked questions after the 2026 MV Hondius Andes hantavirus cluster reached international news is whether a person who suspects they have been exposed can do a rapid hantavirus test at home, the way they would do a home COVID-19 antigen swab. The short answer is no. The longer answer — what actually diagnoses hantavirus pulmonary syndrome (HPS), and what to do if you suspect exposure — is more useful and is what this guide covers.
The short answer: there is no FDA-cleared at-home hantavirus rapid test
As of May 2026 there is no FDA-cleared, CE-IVD-marked, or WHO-prequalified at-home rapid antigen or PCR test for any hantavirus strain — including Andes virus (the strain behind the MV Hondius cluster), Sin Nombre virus (the predominant North American strain), Puumala or Dobrava (the predominant European strains), or Hantaan and Seoul (the predominant Asian strains). The commercial home rapid-test industry that emerged during the COVID-19 pandemic has not produced an equivalent hantavirus product, and the published research-use-only (RUO) work on lateral-flow hantavirus IgM tests has not crossed into a commercial regulatory pathway.
How hantavirus is actually diagnosed
Hantavirus diagnosis is made in a clinical reference laboratory using one of two assay families, sometimes both. The first is IgM and IgG serology: detection of hantavirus-specific antibodies in serum from a venous blood draw, typically by enzyme-linked immunosorbent assay (ELISA) or immunofluorescence assay (IFA). IgM appears in serum within the first week of symptom onset for most patients and is the workhorse confirmatory marker in the acute setting; IgG appears later and is used for surveillance and seroprevalence work. The second is reverse-transcriptase PCR (RT-PCR) detection of hantavirus RNA in serum or whole blood, which can confirm an acute infection within the first week of symptom onset and is the gold-standard genotyping assay (the assay that distinguishes Andes from Sin Nombre, Puumala, or Hantaan).
Which reference labs run these assays
In the Americas, the US CDC Viral Special Pathogens Branch laboratory in Atlanta is the highest-throughput reference lab for both Andes and Sin Nombre. State public-health labs in New Mexico, Arizona, Colorado, California, Washington, Texas, Utah and Montana run hantavirus IgM/IgG ELISA and forward samples to CDC for RT-PCR confirmation. In Argentina the Instituto Nacional de Enfermedades Virales Humanas Dr Julio I. Maiztegui in Pergamino is the national reference centre; in Chile the Instituto de Salud Pública in Santiago performs the same role. For the 2026 MV Hondius cluster, the National Institute for Communicable Diseases (NICD) in Johannesburg has been the lead diagnostic laboratory in collaboration with Geneva University Hospitals (HUG) and the WHO laboratory network.
Why a home test doesn't exist yet
The commercial economics of a home hantavirus rapid test are not currently favourable. The annual global incidence of HPS is small relative to the diseases that have justified home rapid-test commercial pipelines: a few hundred cases per year in the Americas, and an order of magnitude more cases per year in Europe and Asia but largely concentrated in rural endemic populations rather than in the consumer market that drives commercial test demand. The technical case for a home hantavirus rapid test would have to clear the same regulatory hurdles a home COVID-19 antigen test cleared — analytic sensitivity validated against laboratory PCR, clinical sensitivity validated in a prospective symptomatic cohort, and a workable sample-handling protocol for a non-laboratory user — and none of those hurdles has been crossed for hantavirus.
The WHO Research & Development Blueprint working group has flagged rapid diagnostic test development as a priority for the Andes virus pipeline, and several research groups have published lateral-flow hantavirus IgM prototypes in research-use-only formats. The 2026 MV Hondius cluster has revived interest in the development pathway, but the regulatory and commercial timelines for any home product are measured in years not weeks.
What to do if you suspect you have been exposed
The right operational rule is straightforward. Same-day medical evaluation in the prodromal phase (fever, severe muscle aches, headache, nausea, fatigue) or at the first sign of respiratory difficulty after a potential exposure inside the past 8 weeks. Tell the clinician explicitly about possible rodent or close-contact hantavirus exposure: where you were, what you were doing, when symptoms began, and any potential contact with an index case or with rodent excreta. Diagnosis will be made by laboratory IgM/IgG serology or RT-PCR ordered by the clinician, not by any self-administered home test.
Early presentation is the highest-yield intervention. The published HPS cohorts have consistently shown that patients hospitalised during the prodromal phase or at the start of the cardiopulmonary phase have meaningfully better outcomes than those who present late. The diagnostic delay that the absence of a home rapid test imposes is small compared to the gain that comes from same-day clinical evaluation and laboratory testing by professionals.
What about a self-administered exposure assessment?
What does exist — and what is useful — is a self-administered exposure assessment: a written checklist of the four major exposure profiles, the typical symptom timeline, and the high-yield red flags. Hanta Hub maintains a guide to the hantavirus exposure timeline that walks through the prodromal-to-cardiopulmonary transition window and the 1-to-8-week incubation distribution, and a PPE checklist for the cleanup setting that is the single most common Sin Nombre exposure scenario in the United States. Those resources are not a substitute for clinical care, but they do let a person triage their own situation before contacting a clinician.
The honest read
The marketing language used in some online listings — "hantavirus rapid test kit," "home hantavirus screen," "DIY hantavirus assay" — does not match a regulated, validated product. As of May 2026 those listings are not selling a real diagnostic test in the regulatory sense, and any positive or negative result they produce is not a defensible basis for medical decision-making. The right tool is same-day evaluation by a clinician who can order a real laboratory IgM/IgG or RT-PCR, and the right operational rule is to not delay that evaluation while waiting for a home product that does not yet exist.